Bayer Suspends Trasylol Marketing At FDA's Behest
Amid mounting concerns over the safety of Bayer Pharmaceuticals Corp.'s Trasylol, the pharmaceutical giant on Monday agreed to temporarily suspend worldwide marketing of the blood-clotting drug pending a review of preliminary...To view the full article, register now.
Already a subscriber? Click here to view full article